Kamada Ltd. (KMDA) Downgraded by ValuEngine to “Sell”
ValuEngine downgraded shares of Kamada Ltd. (NASDAQ:KMDA) from a hold rating to a sell rating in a research report released on Friday morning.
A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Kamada from a hold rating to a strong sell rating in a report on Thursday, May 18th. TheStreet cut Kamada from a c- rating to a d+ rating in a report on Tuesday, August 1st. Finally, Jefferies Group LLC restated a buy rating and issued a $9.00 target price on shares of Kamada in a report on Wednesday, May 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $7.67.
Shares of Kamada (NASDAQ KMDA) traded up 1.11% during mid-day trading on Friday, hitting $4.55. The stock had a trading volume of 92,330 shares. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a 50 day moving average price of $4.74 and a 200 day moving average price of $6.40. The firm’s market cap is $170.17 million.
Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.01. The business had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The company’s quarterly revenue was up 70.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) EPS. Equities analysts forecast that Kamada will post $0.06 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Nexthera Capital LP acquired a new stake in shares of Kamada during the second quarter valued at approximately $1,805,000. Acadian Asset Management LLC purchased a new stake in Kamada during the first quarter worth about $575,000. Norges Bank purchased a new stake in Kamada during the fourth quarter worth about $377,000. Navellier & Associates Inc purchased a new stake in Kamada during the second quarter worth about $303,000. Finally, Renaissance Technologies LLC boosted its stake in Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after buying an additional 37,800 shares during the last quarter. 7.15% of the stock is owned by institutional investors and hedge funds.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.